Poster-Disease-modifying Therapy
October 25, 2021
Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Expand Study
Background: Siponimod is a selective S1P receptor (S1P1 and S1P5) modulator, approved in the USA for treatment of relapsing forms of MS,...
Poster-Disease-modifying Therapy
October 25, 2021
Multiple Sclerosis Patients Initiating Ofatumumab in the Real-World: Early 3 Months Data
Background: The efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. This analysis provides the first account...
Poster-Disease-modifying Therapy
October 25, 2021
Assessing the Impact of Fingolimod Adherence on Relapse and Costs Using Marginal Structural Models
Background: Disease modifying therapies (DMTs) for relapsing MS are most effective when patients adhere to them as prescribed. Published...
Poster-Disease-modifying Therapy
October 25, 2021
Psoriasis in Multiple Sclerosis Patients Treated with Disease Modifying Therapies
Background: Psoriasis may be more common in people living with multiple sclerosis (PwMS) than in the general population. Some pathways...
Poster-Disease-modifying Therapy
October 25, 2021
Dual Mode of Action of Siponimod in Secondary Progressive Multiple Sclerosis: A Hypothesis Based on the Relevance of Pharmacological Properties
Background: Siponimod, a potent and selective sphingosine 1-phosphate (S1P1,5) receptor modulator, is the first oral disease-modifying...
Poster-Disease-modifying Therapy
October 25, 2021
Post-Approval Safety of Subcutaneous Interferon ?-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections
Background: Subcutaneous interferon ?-1a (sc IFN ?-1a) is a well-established disease-modifying therapy for relapsing multiple sclerosis...
Poster-Disease-modifying Therapy
October 25, 2021
Opportunities and Pitfalls in the Assessment of Brain Atrophy in Dimethyl Fumarate-Treated Relapsing Multiple Sclerosis Patients Using Real-World Data
Background: The majority of real-world data (RWD) on disease-modifying treatments (DMTs) for multiple sclerosis (MS) is based on clinical...
Poster-Disease-modifying Therapy
October 25, 2021
Alopecia in Multiple Scleoris Patients Treated with Disease Modifying Therapies
Background: There is limited literature about the frequency of alopecia in people with multiple sclerosis (MS) treated with disease...
Poster-Disease-modifying Therapy
October 25, 2021
Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem
Background: Dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefitrisk profile in patients with relapsing-remitting...
Poster-Disease-modifying Therapy
October 25, 2021
Incidence and Severity of Natalizumab Infusion-Related Reactions during Infusion and Postinfusion Observation
Background: Natalizumab, an efficacious treatment for relapsing forms of multiple sclerosis, has an approved dosing of 300 mg infused...